EcoDrugPlus

Tyrosine Kinase 2

Ensembl ID : ENSORLG00000005519
Gene Symbol: TYK2
4 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSORLG00000010699
Gene Symbol: TIE1
4 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSORLG00000013453
Gene Symbol: LOC101157019
4 Cross references
191 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSORLG00000027509
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSORLG00000014172
Gene Symbol: AKT2
4 Cross references
210 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSORLG00000011104
Gene Symbol: RELA
4 Cross references
199 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSORLG00000016183
Gene Symbol: SRC
4 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSORLG00000016887
Gene Symbol: VEGFAB
4 Cross references
201 Possible Orthologues:

Vitamin D (1,25- Dihydroxyvitamin D3) Receptor

Ensembl ID : ENSORLG00000016402
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D Receptor Alpha

Ensembl ID : ENSORLG00000001063
Gene Symbol: VDRALPHA
3 Cross references
388 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSORLG00000006556
Gene Symbol: VKORC1
4 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSORLG00000029925
Gene Symbol: LOC101163462
3 Cross references
68 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).